Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
Conditions:   Malignant Thyroid Gland Neoplasm;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Anaplastic Carcinoma;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Papillary Carcinoma;   Thyroid Gland Squamous Cell Carcinoma
Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Selpercatinib;   Procedure: Therapeutic Conventional Surgery
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 19, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments